Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour

Acta Oncologica

Volumn 51, Issue 4, 2012, Pages 550-554

  Constantinidou, Anastasia ^a   Jones, Robin L ^b   Olmos, David ^a   Thway, Khin ^a   Fisher, Cyril ^a   Al Muderis, Omar ^a   Judson, Ian ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AXITINIB; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; IMATINIB; OLAPARIB; PACLITAXEL; SEMAXANIB; SUNITINIB; TEMOZOLOMIDE; TOSEDOSTAT; TRABECTEDIN; VINCRISTINE;

ADVANCED CANCER; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; HEART FAILURE; HUMAN; LETTER; METASTASIS; MUCOSA INFLAMMATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SOLITARY FIBROUS TUMOR; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, FIBROUS TISSUE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84859758049     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.626450     Document Type: Letter

References (16)

1. Fletcher CD. The evolving classifi cation of soft tissue tumours: An update based on the new WHO classifi cation. Histopathology 2006;48:3-12.
2. Spitz FR, Bouvet M, Pisters PW, Pollock RE, Feig BW. Hemangiopericytoma: A 20-year single-institution experience. Ann Surg Oncol 1998;5:350-5.
3. Espat NJ, Lewis JJ, Leung D, Woodruff JM, Antonescu CR, Shia J, et al. Conventional hemangiopericytoma: Modern analysis of outcome. Cancer 2002;95:1746-51.
4. Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG. Management of recurrent meningeal hemangiopericytoma. Cancer 1998;82:1915-20.
5. Magdeleinat P, Alifano M, Petino A, Le Rochais JP, Dulmet E, Galateau F, et al. Solitary fi brous tumors of the pleura: Clinical characteristics, surgical treatment and outcome. Eur J Cardiothorac Surg 2002;21:1087-93.
6. Wong PP, Yagoda A. Chemotherapy of malignant hemangiopericytoma. Cancer 1978;41:1256-60.
7. Peixoto Callejo I. Peritoneal solitary fi brous tumour (SFT): Long-term survival of recurrent and metastasised SFT treated with cytoreductive surgery and intraperitoneal chemotherapy. Clin Transl Oncol 2009;11:250-2.
8. Kozuka T, Kiura K, Katayama H, Fujii N, Ishimaru F, Ikeda K, et al. Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma. Anticancer Res 2002;22: 2939-44.
9. Jones RL, Olmos D, Thway K, Fisher C, Tunariu N, Postel-Vinay S, et al. Clinical benefi t of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemother Pharmacol 2011;68:423-9.
10. Chamberlain MC, Glantz MJ. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. Neurosurgery 2008;63:720 - 6; author reply 26-7.
11. Lackner H, Urban C, Dornbusch HJ, Schwinger W, Kerbl R, Sovinz P. Interferon alfa-2a in recurrent metastatic hemangiopericytoma. Med Pediatr Oncol 2003;40:192-4.
12. Kirn DH, Kramer A. Long-term freedom from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma. J Natl Cancer Inst 1996;88:764-5.
13. Park MS , Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, et al. Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/ malignant solitary fi brous tumor [abstract]. J Clin Oncol 2008;26:10512.
14. Ryan CW, von Mehren M, Rankin CJ, Goldblum JR, Demetri GD, Bramwell VH, et al. Phase II intergroup study of sorafenib in advanced soft tissue sarcomas: SWOG 0505 [abstract]. J Clin Oncol 2008;26:10532.
15. Mulamalla K, Truskinovsky AM, Dudek AZ. Rare case of hemangiopericytoma responds to sunitinib. Transl Res 2008; 151:129-33.
16. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009;27:3126-32.